Skip to main content
SpringerLink
Log in

Cytokines and Growth Factors

  • Chapter
  • First Online:
Current Applications of Pharmaceutical Biotechnology

Part of the book series: Advances in Biochemical Engineering/Biotechnology ((ABE,volume 171))

Abstract

Several cytokines have been used to treat autoimmune diseases, viral infections, and cancer and to regenerate the skin. In particular, interferons (INFs) have been used to treat cancer, hepatitis B and C, and multiple sclerosis, while interleukins (ILs) and tumor necrosis factors (TNFs) have been used in the management of different types of cancer. Concerning the hematopoietic growth factors (HGFs), epoetin has been used for anemia, whereas the colony-stimulating factors (CSFs) have been used for neutropenia. Other growth factors have been extensively explored, although most still need to demonstrate in vivo clinical relevance before reaching the market.

This chapter provides an overview on the therapeutic applications of biological medicines containing recombinant cytokines and growth factors (HGFs and others). From this review, we concluded that the clinical relevance of recombinant cytokines has been increasing. Since the 1980s, the European Medicines Agency (EMA) and/or Food and Drug Administration (FDA) have approved 89 biological medicines containing recombinant cytokines. Among these, 18 were withdrawn, 24 are biosimilars, and 18 are orphans.

So far, considerable progress has been made in discovering new cytokines, additional cytokine functions, and how they interfere with human diseases. Future prospects include the approval of more biological and biosimilar medicines for different therapeutic applications.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Chen Y-C, Yeh M-K (2018) Introductory chapter: biopharmaceuticals. In: Chen Y-C, Yeh M-K (eds) Biopharmaceuticals. IntechOpen, London

    Google Scholar 

  2. Walsh G (2013) Pharmaceutical biotechnology: concepts and applications. Wiley, Hoboken

    Google Scholar 

  3. FDA (2019) What are “Biologics” questions and answers. https://www.fda.gov/about-fda/about-center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers

  4. EMA (2019) Biological medicine. https://www.ema.europa.eu/en/glossary/biological-medicine

  5. FDA (2019) Complete list of licensed products and establishments. https://www.fda.gov/vaccines-blood-biologics/complete-list-licensed-products-and-establishments

  6. EMA (2019) Orphan designation: overview. https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview

  7. EMA (2019) Biosimilar medicines: overview. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview

  8. Santos SB, Lobo JMS, Silva AC (2019) Biosimilar medicines used for cancer therapy in Europe: a review. Drug Discov Today 24(1):293–299

    Article  CAS  PubMed  Google Scholar 

  9. Silk AW, Margolin K (2019) Cytokine therapy. Hematol Oncol Clin 33:261–274

    Article  Google Scholar 

  10. O’Shea JJ, Gadina M, Siegel RM (2019) 9 – Cytokines and cytokine receptors. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM (eds) Clinical immunology5th edn. Elsevier, London, pp 127–55.e1

    Google Scholar 

  11. Lipiäinen T, Peltoniemi M, Sarkhel S, Yrjönen T, Vuorela H, Urtti A et al (2015) Formulation and stability of cytokine therapeutics. J Pharm Sci 104(2):307–326

    Article  PubMed  CAS  Google Scholar 

  12. Hutmacher C, Neri D (2018) Antibody-cytokine fusion proteins: biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev. https://doi.org/10.1016/j.addr.2018.09.002

  13. Moorkens E, Meuwissen N, Huys I, Declerck P, Vulto AG, Simoens S (2017) The market of biopharmaceutical medicines: a snapshot of a diverse industrial landscape. Front Pharmacol 8:314

    Article  PubMed  PubMed Central  Google Scholar 

  14. Crommelin DJA, Sindelar RD, Meibohm B (2013) Pharmaceutical biotechnology fundamentals and applications. Taylor & Francis, Milton Park

    Book  Google Scholar 

  15. Ryff J-C, Bordens RW, Pestka S (2013) Interferons and interleukins. In: Crommelin DJA, Sindelar RD, Meibohm B (eds) Pharmaceutical biotechnology: fundamentals and applications. Interferons and interleukins, vol 3 edn. Informa Healthcare, New York

    Google Scholar 

  16. EMA (2012) EPAR summary for the public: Intron A interferon alfa 2b. https://www.ema.europa.eu/en/documents/overview/introna-epar-summary-public_en.pdf

  17. EMA (2008) European Public Assessment Assessment (EPAR): viraferon. https://www.ema.europa.eu/en/documents/overview/viraferon-epar-summary-public_en.pdf

  18. EMA (2017) EPAR summary for the public: Pegasys (peginterferon alfa-2a). https://www.ema.europa.eu/en/documents/overview/pegasys-epar-summary-public_en.pdf

  19. EMA (2006) Public statement on infergen: interferon alfacon-1. https://www.ema.europa.eu/en/documents/public-statement/public-statement-infergen-interferon-alfacon-1-withdrawal-marketing-authorisation-european-union_en.pdf

  20. FDA (2008) ROFERON®-A: Interferon alfa-2a, recombinant

    Google Scholar 

  21. EMA (2012) EPAR summary for the public: PegIntron (peginterferon alfa-2b). https://www.ema.europa.eu/en/documents/overview/pegintron-epar-summary-public_en.pdf

  22. Corporation MSD (2015). Sylatron™ (peginterferon alfa-2b). https://www.merck.com/product/usa/pi_circulars/s/sylatron/sylatron_pi.pdf

  23. Biopharma H (2019) Alferon N injection® (Interferon alfa-n3). https://hemispherx.net/products/

    Google Scholar 

  24. EMA (2012) EPAR summary for the public: Betaferon (interferon beta-1b). https://www.ema.europa.eu/en/documents/overview/betaferon-epar-summary-public_en.pdf

  25. EMA (2011) EPAR summary for the public: Avonex (interferon beta-1a). https://www.ema.europa.eu/en/documents/overview/avonex-epar-summary-public_en.pdf

  26. EMA (2014) EPAR summary for the public: rebif (interferon beta-1a). https://www.ema.europa.eu/en/documents/overview/rebif-epar-summary-public_en.pdf

  27. EMA (2014) EPAR summary for the public: Plegridy (peginterferon beta-1a). https://www.ema.europa.eu/en/documents/overview/plegridy-epar-summary-public_en.pdf

  28. EMA (2012) EPAR summary for the public: Extavia (interferon beta-1b). https://www.ema.europa.eu/en/documents/overview/extavia-epar-summary-public_en.pdf

  29. Horizon Pharma (2018) Actimmune® (Interferon gamma-1b). https://www.actimmune.com/

  30. National Health Service (NHS) (2018) E. clinical commissioning policy: anakinra to treat periodic fevers and autoinflammatory diseases (all ages)

    Google Scholar 

  31. National Health Service (NHS) (2018) E. clinical commissioning policy: anakinra/tocilizumab for the treatment of adult-onset Still’s disease refractory to second-line therapy (adults)

    Google Scholar 

  32. EMA (2009) Kineret (anakinra): an overview of Kineret and why it is authorised in the EU. https://www.ema.europa.eu/en/documents/overview/kineret-epar-medicine-overview_en.pdf

  33. EMA (2008) Public summary of positive opinion for orphan designation of human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and nonglycosylated) (inhalation use) for the treatment of renal cell carcinoma. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/06/417-public-summary-positive-opinion-orphan-designation-human-interleukin-2-glycosylated_en.pdf

  34. FDA (2014) Current and resolved drug shortages and discontinuations reported to FDA. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Denileukin+Diftitox+%28Ontak%29+Injection&st=d&tab=tabs-2

  35. EMA (2015) Public summary of opinion on orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein for the treatment of acute myeloid leukaemia

    Google Scholar 

  36. Agency EM (2014) Public summary of opinion on orphan designation: recombinant human interleukin-7 for the treatment of progressive multifocal leukoencephalopathy. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/12/1013-public-summary-opinion-orphan-designation-recombinant-human-interleukin-7-treatment-progressive_en.pdf

    Google Scholar 

  37. EMA (2017) Public summary of opinion on orphan designation: recombinant human interleukin-7 fused to a hybrid crystallisable fragment region of a human antibody for treatment of idiopathic CD4 lymphocytopenia. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/17/1875-public-summary-opinion-orphan-designation-recombinant-human-interleukin-7-fused-hybrid_en.pdf

  38. EMA (2017) Public summary of opinion on orphan designation: pegylated recombinant human interleukin-10 for the treatment of pancreatic cancer. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/16/1804-public-summary-opinion-orphan-designation-pegylated-recombinant-human-interleukin-10-treatment_en.pdf

  39. EMA (2016) Public summary of opinion on orphan designation: recombinant human interleukin-12 for treatment of acute radiation syndrome. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/16/1727-public-summary-opinion-orphan-designation-recombinant-human-interleukin-12-treatment-acute_en.pdf

  40. EMA (2017) European public assessment report (EPAR): Beromun. https://www.ema.europa.eu/en/documents/overview/beromun-epar-summary-public_en.pdf

  41. EMA (2017). Withdrawal of the marketing authorisation application for Zafiride (NGR-human tumour necrosis factor alpha). https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-zafiride-ngr-human-tumour-necrosis_en.pdf

  42. EMA (2008) Public summary of positive opinion for orphan designation of NGR-human tumour necrosis factor for the treatment of malignant mesothelioma. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/08/549-public-summary-positive-opinion-orphan-designation-ngr-human-tumour-necrosis-factor-treatment_en.pdf

  43. EMA (2009) Public summary of positive opinion for orphan designation of NGR-human tumour necrosis factor for the treatment of hepatocellular carcinoma. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/09/686-public-summary-positive-opinion-orphan-designation-ngr-human-tumour-necrosis-factor-treatment_en.pdf

  44. Brar K, Leung DYM (2016) Recent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis. Expert Opin Biol Ther 16(4):507–514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Mufarrege EF, Haile LA, Etcheverrigaray M, Verthelyi DI (2019) Multiplexed gene expression as a characterization of bioactivity for interferon beta (IFN-β) biosimilar candidates: impact of innate immune response modulating impurities (IIRMIs). AAPS J 21(2):26

    Article  PubMed  CAS  Google Scholar 

  46. Asadullah K, Sterry W, Trefzer U (2002) Cytokines: interleukin and interferon therapy in dermatology. Clin Exp Dermatol 27(7):578–584

    Article  CAS  PubMed  Google Scholar 

  47. Steen-Louws C, Hartgring SAY, Popov-Celeketic J, Lopes AP, de Smet MBM, Eijkelkamp N et al (2019) IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10. Clin Exp Immunol 195(1):1–9

    Article  CAS  PubMed  Google Scholar 

  48. Gao B, Xiang X (2018) Interleukin-22 from bench to bedside: a promising drug for epithelial repair. Cell Mol Immunol 16:666–667

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  49. Tang K-Y, Lickliter J, Huang Z-H, Xian Z-S, Chen H-Y, Huang C et al (2019) Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects. Cell Mol Immunol 16:473–482

    Article  CAS  PubMed  Google Scholar 

  50. Zhang H, Wang Y, Hwang ES, He Y-W (2016) Interleukin-10: an immune-activating cytokine in cancer immunotherapy. J Clin Oncol 34(29):3576–3578

    Article  CAS  PubMed  Google Scholar 

  51. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ et al (2016) Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol 34(29):3562–3569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Pembrolizumab and Recombinant Interleukin-12 in Treating Patients with Solid Tumors [Internet] (2019). https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2017-00091&r=1

  53. Coyne GHOS, Conlon K, Takebe N, Streicher H, Quinn MF, Bruns A et al (2018) Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers. J Clin Oncol 36(15_suppl):TPS3128–TPS3TPS

    Article  Google Scholar 

  54. Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA et al (2018) A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors. Clin Cancer Res 24(7):1525–1535

    Article  CAS  PubMed  Google Scholar 

  55. Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J et al (2018) Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3(5):e98960

    Article  PubMed Central  Google Scholar 

  56. Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V et al (2019) Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of interleukin 1 blockade in acute severe colitis: the IASO trial. BMJ Open 9(2):e023765

    Article  PubMed  PubMed Central  Google Scholar 

  57. Zhu J, Huang J, Dai D, Wang X, Gao J, Han W et al (2019) Recombinant human interleukin-1 receptor antagonist treatment protects rats from myocardial ischemia–reperfusion injury. Biomed Pharmacother 111:1–5

    Article  CAS  PubMed  Google Scholar 

  58. Humrich JY, Riemekasten G (2019) Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 31(2):208–212

    Article  CAS  PubMed  Google Scholar 

  59. Zhang R, Xi X, Wang C, Pan Y, Ge C, Zhang L et al (2018) Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: a systematic review and meta-analysis. PLoS One 13(7):e0201025

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Yu K-M, Lau JY-N, Fok M, Yeung Y-K, Fok S-P, Zhang S et al (2018) Preclinical evaluation of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys. Toxicol Appl Pharmacol 342:39–49

    Article  CAS  PubMed  Google Scholar 

  61. NCI (2019) NCI dictionary of cancer terms: tumor necrosis factor. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor-necrosis-factor

  62. Li Q, Sun W, Yuan D, Lv T, Yin J, Cao E et al (2016) Efficacy and safety of recombinant human tumor necrosis factor application for the treatment of malignant pleural effusion caused by lung cancer. Thorac Cancer 7(1):136–139

    Article  CAS  PubMed  Google Scholar 

  63. Foote M (2013) Hematopoietic growth factors. In: Crommelin DJA, Sindelar RD, Meibohm B (eds) Pharmaceutical biotechnology: fundamentals and applications3rd edn. Informa Healthcare, London

    Google Scholar 

  64. Groopman JE, Molina J-M, Scadden DT (1989) Hematopoietic growth factors. N Engl J Med 321(21):1449–1459

    Article  CAS  PubMed  Google Scholar 

  65. Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354(19):2034–2045

    Article  CAS  PubMed  Google Scholar 

  66. EMA (2018) Epoetin Alfa Hexal (epoetin alfa): an overview of Epoetin Alfa Hexal and why it is authorised in the EU. https://www.ema.europa.eu/en/documents/overview/epoetin-alfa-hexal-epar-summary-public_en-0.pdf

  67. EMA (2018) Abseamed (epoetin alfa): an overview of Abseamed and why it is authorised in the EU

    Google Scholar 

  68. EMA (2018) Binocrit (epoetin alfa): an overview of Binocrit and why it is authorised in the EU. https://www.ema.europa.eu/en/documents/overview/binocrit-epar-medicine-overview_en.pdf

  69. FDA (2017) Information for epogen/procrit (epoetin alfa). https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm541173.htm

  70. EMA (2015) EPAR summary for the public: NeoRecormon – epoetin beta. https://www.ema.europa.eu/en/documents/overview/neorecormon-epar-summary-public_en.pdf

  71. EMA (2012) EPAR summary for the public: mircera – methoxy polyethylene glycol-epoetin beta. https://www.ema.europa.eu/en/documents/overview/mircera-epar-summary-public_en.pdf

  72. FDA (2018) FDA approves Mircera for anemia associated with chronic kidney disease in pediatric patients on dialysis. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610210.htm

  73. EMA (2009) EPAR summary for the public: eporatio – epoetin theta. https://www.ema.europa.eu/en/documents/overview/eporatio-epar-summary-public_en.pdf

  74. EMA (2009) EPAR summary for the public: biopoin – epoetin theta. https://www.ema.europa.eu/en/documents/overview/biopoin-epar-summary-public_en.pdf

  75. EMA (2019) Silapo (epoetin zeta): an overview of Silapo and why it is authorised in the EU. https://www.ema.europa.eu/en/documents/overview/silapo-epar-medicine-overview_en.pdf

  76. EMA (2011) EPAR summary for the public: retacrit – epoetin zeta. https://www.ema.europa.eu/en/documents/overview/retacrit-epar-summary-public_en.pdf

  77. FDA (2018) FDA approves first epoetin alfa biosimilar for the treatment of anemia. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607703.htm

  78. EMA (2013) EPAR summary for the public: Aranesp – darbepoetin alfa. https://www.ema.europa.eu/en/documents/overview/aranesp-epar-summary-public_en.pdf

  79. EMA (2009) EPAR summary for the public: NESPO – darbepoetin alfa. https://www.ema.europa.eu/en/documents/overview/nespo-epar-summary-public_en.pdf

  80. FDA (2017) Information for Aranesp (darbepoetin alfa). https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm541148.htm

  81. EMA (2017) EPAR summary for the public: Biograstim. https://www.ema.europa.eu/en/documents/overview/biograstim-epar-summary-public_en.pdf

  82. EMA (2008) EPAR summary for the public: Tevagrastim. https://www.ema.europa.eu/en/documents/overview/tevagrastim-epar-summary-public_en.pdf

  83. EMA (2014) EPAR summary for the public: Zarzio. https://www.ema.europa.eu/en/documents/overview/zarzio-epar-summary-public_en.pdf

  84. EMA (2014) EPAR summary for the public: Ratiograstim. https://www.ema.europa.eu/en/documents/overview/ratiograstim-epar-summary-public_en.pdf

  85. EMA (2018) EPAR summary for the public: Grastofil. https://www.ema.europa.eu/en/documents/overview/grastofil-epar-medicine-overview_en.pdf

  86. EMA (2010) EPAR summary for the public: Nivestim. https://www.ema.europa.eu/en/documents/overview/nivestim-epar-summary-public_en.pdf

  87. EMA (2014) EPAR summary for the public: Accofil. https://www.ema.europa.eu/en/documents/overview/accofil-epar-summary-public_en.pdf

  88. EMA (2014) EPAR summary for the public: Filgrastim Hexal. https://www.ema.europa.eu/en/documents/overview/filgrastim-hexal-epar-summary-public_en.pdf

  89. EMA (2011) EPAR summary for the public: Filgrastim Ratiopharm. https://www.ema.europa.eu/en/documents/overview/filgrastim-ratiopharm-epar-summary-public_en.pdf

  90. FDA (2015) FDA approves Neupogen for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident. https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/AboutMCMi/ucm443245.htm

  91. FDA (2015) Prescribing information for Zarxio. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125553lbl.pdf

  92. FDA (2018) Prescribing information for Nivestym. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761080s000lbl.pdf

  93. EMA (2015) Public summary of opinion on orphan designation: filgrastim for the treatment of amyotrophic lateral sclerosis. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/08/532-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-amyotrophic-lateral_en.pdf

  94. EMA (2015) Public summary of opinion on orphan designation: Filgrastim for the treatment of spinal cord injury. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/08/580-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-spinal-cord-injury_en.pdf

  95. EMA (2018) EPAR summary for the public: Fulphila (pegfilgrastim). https://www.ema.europa.eu/en/documents/overview/fulphila-epar-medicine-overview_en.pdf

  96. FDA (2018) Prescribing information for Fulphila. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761075s000lbl.pdf

  97. EMA. EPAR summary for the public: Udenyca (pegfilgrastim). https://www.ema.europa.eu/en/documents/overview/udenyca-epar-medicine-overview_en.pdf

  98. FDA (2018) Prescribing information for UDENYCA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761039s000lbl.pdf

  99. EMA (2018) EPAR summary for the public: Ziextenzo (pegfilgrastim). https://www.ema.europa.eu/en/documents/overview/ziextenzo-epar-medicine-overview_en.pdf

  100. EMA (2018) EPAR summary for the public: Pelgraz (pegfilgrastim). https://www.ema.europa.eu/en/documents/overview/pelgraz-epar-medicine-overview_en.pdf

  101. EMA (2018) EPAR summary for the public: Pelmeg (pegfilgrastim). https://www.ema.europa.eu/en/documents/overview/pelmeg-epar-medicine-overview_en.pdf

  102. EMA (2015) EPAR summary for the public: Ristempa (pegfilgrastim). https://www.ema.europa.eu/en/documents/overview/ristempa-epar-summary-public_en.pdf

  103. EMA (2009) EPAR summary for the public: Neupopeg (pegfilgrastim). https://www.ema.europa.eu/en/documents/overview/neupopeg-epar-summary-public_en.pdf

  104. EMA (2018) Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim). https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-efgratin-pegfilgrastim_en-0.pdf

  105. EMA (2018) Withdrawal of the marketing authorisation application for Cavoley (pegfilgrastim). https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-cavoley-pegfilgrastim_en-0.pdf

  106. EMA (2018) EPAR summary for the public: Neulasta (pegfilgrastim). https://www.ema.europa.eu/en/documents/overview/neulasta-epar-medicine-overview_en.pdf

  107. EMA (2013) EPAR summary for the public: Lonquex (lipegfilgrastim). https://www.ema.europa.eu/en/documents/overview/lonquex-epar-summary-public_en.pdf

  108. FDA (2012) Prescribing information for Granix. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125294s0000lbl.pdf

  109. EMA (2016) Public summary of opinion on orphan designation: Molgramostim for the treatment of acute respiratory distress syndrome. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/16/1685-public-summary-opinion-orphan-designation-molgramostim-treatment-acute-respiratory-distress_en.pdf

  110. FDA (2018) https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMIssues/ucm602102.htm. https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMIssues/ucm602102.htm

  111. Burchiel SW, Aspbury R, Munday J (2019) The search for biosimilars and biobetters. Drug Discov Today 24:1087–1091

    Article  PubMed  Google Scholar 

  112. Siegel JF, Royzman I (2017) Biosimilar approvals in Europe. https://www.biologicsblog.com/2017-biosimilar-approvals-in-europe

    Google Scholar 

  113. Affentranger L, Bohlius J, Hallal M, Bonadies N (2019) Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: a systematic review. Crit Rev Oncol Hematol 136:37–47

    Article  PubMed  Google Scholar 

  114. Hamel S, Kuo V, Sawinski D, Johnson D, Bloom RD, Bleicher M et al (2019) Single center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation. Clin Transpl 33:e13541

    Article  CAS  Google Scholar 

  115. Kamath MS, Kirubakaran R, Sunkara SK (2018) Granulocyte-colony stimulating factor administration for subfertile women undergoing assisted reproduction. Cochrane Database Syst Rev 12. https://doi.org/10.1002/14651858.CD013226

  116. Zhang L, Xu W-H, Fu X-H, Huang Q-X, Guo X-Y, Zhang L et al (2018) Therapeutic role of granulocyte colony-stimulating factor (G-CSF) for infertile women under in vitro fertilization and embryo transfer (IVF-ET) treatment: a meta-analysis. Arch Gynecol Obstet 298(5):861–871

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Herrmann M, Zeiter S, Eberli U, Hildebrand M, Camenisch K, Menzel U et al (2018) Five days granulocyte colony-stimulating factor treatment increases bone formation and reduces gap size of a rat segmental bone defect: a pilot study. Front Bioeng Biotechnol 6:5

    Article  PubMed  PubMed Central  Google Scholar 

  118. Biotech B (2019) Patient product information: REGEN-D® 150. https://www.bharatbiotech.com/images/regend150/REGEN-D150_ppi.pdf

    Google Scholar 

  119. Biotech B (2019) Patient product information: REGEN-D® 60. https://www.bharatbiotech.com/images/regend60/regen-d%2060-ppi.pdf

    Google Scholar 

  120. Berlanga J, Férnandez J, López E, López P, del Río A, Valenzuela C et al (2013) Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC Rev 15(1):11–15

    Article  PubMed  Google Scholar 

  121. Yamakawa S, Hayashida K (2019) Advances in surgical applications of growth factors for wound healing. Burns Trauma 7(1):10

    PubMed  PubMed Central  Google Scholar 

  122. EMA (2017) EMA decision of 30 January 2018 on the granting of a product specific waiver for recombinant human epidermal growth factor. https://www.ema.europa.eu/en/documents/pip-decision/p/0038/2018-ema-decision-30-january-2018-granting-product-specific-waiver-recombinant-human-epidermal_en.pdf

  123. Esquirol-Caussa J, Herrero-Vila E (2019) Human recombinant epidermal growth factor in skin lesions: 77 cases in EPItelizando project. J Dermatol Treat 30(1):96–101

    Article  CAS  Google Scholar 

  124. Öhnstedt E, Lofton Tomenius H, Vågesjö E, Phillipson M (2019) The discovery and development of topical medicines for wound healing. Expert Opin Drug Discovery 14(5):485–497

    Article  CAS  Google Scholar 

  125. EMA (2012) EPAR summary for the public: Regranex (becaplermin). https://www.ema.europa.eu/en/documents/overview/regranex-epar-summary-public_en.pdf

  126. EMA (2012) Public statement on Regranex (becaplermin): withdrawal of the marketing authorisation in the European Union. https://www.ema.europa.eu/en/documents/public-statement/public-statement-regranex-withdrawal-marketing-authorisation-european-union_en.pdf

  127. FDA (2018) Summary of safety and effectiveness data: Augment® Injectable. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100006S005b.pdf

  128. Sun H, Lu P-P, Zhou P-H, Sun S-W, Zhang H-T, Liu Y-J et al (2017) Recombinant human platelet-derived growth factor-BB versus autologous bone graft in foot and ankle fusion: a systematic review and meta-analysis. Foot Ankle Surg 23(1):32–39

    Article  PubMed  Google Scholar 

  129. Biologics L (2019) GEM 21S®. https://lynchbiologics.com/products/gem-21s/

    Google Scholar 

  130. KAKEN Pharmaceutical CO (2019) L. Fiblast® (Recombinant human basic fibroblast growth factor, rh bFGF). http://www.kaken.co.jp/english/business/rd_pipeline.html

  131. EMA (2014) Public summary of opinion on orphan designation: variant of recombinant human fibroblast growth factor 19 for the treatment of primary biliary cirrhosis. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/14/1329-public-summary-opinion-orphan-designation-variant-recombinant-human-fibroblast-growth-factor-19_en.pdf

  132. Agency EM (2016) Public summary of opinion on orphan designation: Variant of recombinant human fibroblast growth factor 19 for the treatment of primary sclerosing cholangitis. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/15/1584-public-summary-opinion-orphan-designation-variant-recombinant-human-fibroblast-growth-factor-19_en.pdf

  133. EMA (2016) EPAR summary for the public: Kepivance (palifermin). https://www.ema.europa.eu/en/documents/overview/kepivance-epar-summary-public_en.pdf

  134. Hanft JR, Pollak RA, Barbul A, van Gils C, Kwon PS, Gray SM et al (2008) Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 17(1):30–37

    Article  CAS  PubMed  Google Scholar 

  135. EMA (2010) Public summary of opinion on orphan designation: Recombinant human vascular endothelial growth factor for the treatment of amyotrophic lateral sclerosis. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/09/711-public-summary-opinion-orphan-designation-recombinant-human-vascular-endothelial-growth-factor_en.pdf

  136. Yeung AWK, Abdel-Daim MM, Abushouk AI, Kadonosono K (2019) A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach. Naunyn Schmiedeberg’s Arch Pharmacol 392(4):393–403

    Article  CAS  Google Scholar 

  137. Hayes Ryan D, McCarthy FP, O'Donoghue K, Kenny LC (2018) Placental growth factor: a review of literature and future applications. Pregnancy Hypertens 14:260–264

    Article  CAS  PubMed  Google Scholar 

  138. Parchem JG, Brock C, Sibai BM (2019) 442: plasma placental growth factor and the risk of adverse perinatal outcome. Am J Obstet Gynecol 220(1, Suppl):S298

    Article  Google Scholar 

  139. EMA (2018) Public summary of opinion on orphan designation: recombinant human placental growth factor for the treatment of pre-eclampsia. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/18/2040-public-summary-opinion-orphan-designation-recombinant-human-placental-growth-factor-treatment_en.pdf

  140. Shpichka A, Butnaru D, Bezrukov EA, Sukhanov RB, Atala A, Burdukovskii V et al (2019) Skin tissue regeneration for burn injury. Stem Cell Res Ther 10(1):94

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. So K, McGrouther DA, Bush JA, Durani P, Taylor L, Skotny G et al (2011) Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial. Plast Reconstr Surg 128(1):163–172

    Article  CAS  PubMed  Google Scholar 

  142. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915

    Article  CAS  PubMed  Google Scholar 

  143. Key T, Appleby P, Reeves G, Roddam A, Endogenous Hormones and Breast Cancer Collaborative Group (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11(6):530–542

    Article  PubMed  CAS  Google Scholar 

  144. Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A et al (2016) A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res 76(8):2288–2300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Schmidt JA, Allen NE, Almquist M, Franceschi S, Rinaldi S, Tipper SJ et al (2014) Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Prev Biomark 23(6):976–985

    Article  CAS  Google Scholar 

  146. Biopharmaceuticals I (2019) INCRELEX®: full prescribing information. https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/sites/9/2019/01/21153952/Increlex_Full_Prescribing_Information1.pdf

  147. FDA (2009) Access to Iplex for patients with ALS. https://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm118117.htm

  148. EMA (2004) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3 for the treatment of Type A extreme insulin resistance syndrome. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/04/236-public-summary-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-type-extreme-insulin-resi_en.pdf

  149. EMA (2011) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I/recombinant human insulin like growth factor binding protein-3 for the treatment of Type B extreme insulin resistance syndrome. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/04/235-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-type-b-extreme-insu_en.pdf

  150. EMA (2004) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I/recombinant human insulin like growth factor binding protein-3 for the treatment of Rabson Mendenhall syndrome. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/04/237-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-rabson-mendnhal_en.pdf

  151. EMA (2011) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3 for the treatment of primary growth hormone insensitivity syndrome (Laron Syndrome). https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/03/159-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-primary-growt_en.pdf

  152. EMA (2011) Public summary of opinion on orphan designation: recombinant human insulin-like growth factor-I/recombinant human insulin like growth factor binding protein-3 for the treatment of leprechaunism. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/04/238-public-summary-positive-opinion-orphan-designation-recombinant-human-insulin-growth-factor-i/recombinant-human-insulin-growth-factor-binding-protein-3-treatment-leprechaunism_en.pdf

  153. Skaper SD (2017) Nerve growth factor: a neuroimmune crosstalk mediator for all seasons. Immunology 151(1):1–15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. EMA (2015) Public summary of opinion on orphan designation: recombinant human nerve growth factor for the treatment of retinitis pigmentosa. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/13/1135-public-summary-opinion-orphan-designation-recombinant-human-nerve-growth-factor-treatment_en.pdf

  155. EMA (2015) Public summary of opinion on orphan designation: recombinant human nerve growth factor for the treatment of neurotrophic keratitis. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/15/1586-public-summary-opinion-orphan-designation-recombinant-human-nerve-growth-factor-treatment_en.pdf

  156. FDA (2018) Prescribing information for OXERVATE. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761094s000lbl.pdf

  157. Mesentier-Louro LA, Rosso P, Carito V, Mendez-Otero R, Santiago MF, Rama P et al (2019) Nerve growth factor role on retinal ganglion cell survival and axon regrowth: effects of ocular administration in experimental model of optic nerve injury. Mol Neurobiol 56(2):1056–1069

    Article  CAS  PubMed  Google Scholar 

  158. Sacchetti M, Lambiase A, Schmidl D, Schmetterer L, Ferrari M, Mantelli F et al (2019) Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2018-312470

  159. Aloe L, Rocco ML, Balzamino BO, Micera A (2016) Nerve growth factor: role in growth, differentiation and controlling cancer cell development. J Exp Clin Cancer Res 35(1):116

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  160. Denk F, Bennett DL, McMahon SB (2017) Nerve growth factor and pain mechanisms. Annu Rev Neurosci 40(1):307–325

    Article  CAS  PubMed  Google Scholar 

  161. Biopharmaceuticals I (2019) Increlex® (mecasermin). https://www.increlex.com/

  162. Insmed (2009) Insmed provides update on supply of IPLEX®. https://web.archive.org/web/20170902142334/http://investor.insmed.com/releasedetail.cfm?releaseid=399059

Download references

Acknowledgments

This work was supported by the Applied Molecular Biosciences Unit-UCIBIO and FP-ENAS, which are financed by national funds from FCT/MCTES (UID/Multi/04378/2019 and UID/Multi/04546/2019, respectively).

Author information

Authors and Affiliations

  1. UCIBIO/REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

    A. C. Silva & J. M. Sousa Lobo

  2. FP-ENAS (UFP Energy, Environment and Health Research Unit), CEBIMED (Biomedical Research Centre), Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal

    A. C. Silva

Authors
  1. A. C. Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Sousa Lobo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. C. Silva .

Editor information

Editors and Affiliations

  1. UCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

    Ana Catarina Silva

  2. FP-ENAS (UFP Energy, Environment and Health Research Unit), CEBIMED (Biomedical Research Centre), Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal

    Ana Catarina Silva

  3. Center for Neurosciences and Cell Biology (CNC) and Faculty of Pharmacy (FFUC), University of Coimbra, Coimbra, Portugal

    João Nuno Moreira

  4. UCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

    José Manuel Sousa Lobo

  5. UCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

    Hugo Almeida

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Silva, A.C., Lobo, J.M.S. (2019). Cytokines and Growth Factors. In: Silva, A.C., Moreira, J.N., Lobo, J.M.S., Almeida, H. (eds) Current Applications of Pharmaceutical Biotechnology. Advances in Biochemical Engineering/Biotechnology, vol 171. Springer, Cham. https://doi.org/10.1007/10_2019_105

Download citation

Publish with us

Policies and ethics

Search

Navigation